Moderna’s Covid-19 vaccine produced antibodies in Phase 1
Moderna finally published the long-awaited data from on its investigational Covid-19 vaccine, demonstrating what experts called an encouraging antibody response.
The study, which enrolled 45 healthy volunteers, found that Moderna’s vaccine led to an average level of neutralizing antibodies above what was seen in patients who had recovered from Covid-19. In the middle dose, the one Moderna is taking to Phase 3, all of the patients experienced mild or moderate side effects.
The big question is whether those antibody responses will actually protect against infection, and how long they'll last. It's also unclear how Moderna’s data compare with the results Pfizer and BioNTech disclosed earlier this month. The effects on antibodies seemed roughly comparable, although experts warned against comparing the two studies, which used different methods.
Read more.
The study, which enrolled 45 healthy volunteers, found that Moderna’s vaccine led to an average level of neutralizing antibodies above what was seen in patients who had recovered from Covid-19. In the middle dose, the one Moderna is taking to Phase 3, all of the patients experienced mild or moderate side effects.
The big question is whether those antibody responses will actually protect against infection, and how long they'll last. It's also unclear how Moderna’s data compare with the results Pfizer and BioNTech disclosed earlier this month. The effects on antibodies seemed roughly comparable, although experts warned against comparing the two studies, which used different methods.
Read more.
.png)
No hay comentarios:
Publicar un comentario